CUREVAC N.V. news, videos and press releases - Page 6
For more news please use our advanced search feature.
CUREVAC N.V. - More news...
CUREVAC N.V. - More news...
- CureVac Streamlines European Network for mRNA Product Manufacturing
- DGAP-News: CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
- CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
- DGAP-News: CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
- DGAP-News: CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
- CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
- DGAP-News: CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
- DGAP-News: CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
- CureVac Announces Voting Results of General Meeting
- DGAP-News: CureVac Announces Voting Results of General Meeting
- DGAP-News: CureVac Provides Supervisory Board Update
- CureVac Provides Supervisory Board Update
- DGAP-News: CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
- CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
- DGAP-News: CureVac Appoints Klaus Edvardsen as Chief Development Officer
- CureVac Appoints Klaus Edvardsen as Chief Development Officer
- DGAP-News: CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
- DGAP-News: CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
- CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
- DGAP-News: CureVac : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
- CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
- DGAP-News: CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
- DGAP-News: CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
- CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
- DGAP-News: CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021
- CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021
- DGAP-News: CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
- CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
